A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY OF A SINGLE INTRAVENOUS DOSE OF SGT-003 IN AMBULANT MALES WITH DUCHENNE MUSCULAR DYSTROPHY
- Registry ID
- SGT-003-301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- SOLID BIOSCIENCES, INC.
- Start date
- 2025-12-29
- Last update
- 2025-08-15
Conditions
- DUCHENNE MUSCULAR DYSTROPHY
Related clinical trials
- A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE COMPARISON AND EXPLORATORY EFFICACY STUDY OF ORALLY ADMINISTERED SAT-3247 IN AMBULATORY DMD PATIENTS
- A PHASE 1/2, OPEN-LABEL, DOSE ESCALATION STUDY TO ASSESS THE SAFETY,
TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE INTRAVENOUS
DOSES OF BMN 351 IN PARTICIPANTS WITH DUCHENNE MUSCULAR DYSTROPHY
- A PHASE 1/2, FIRST IN HUMAN, MULTIPLE-DOSE, 2-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NS-050/NCNP-03 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)
- A PHASE 2 STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, AND
PHARMACOKINETICS OF NS-089/NCNP-02 IN BOYS WITH DUCHENNE MUSCULAR
DYSTROPHY (DMD)
- A PHASE 1/2/3 OPEN-LABEL, STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF INTRAVENOUS RGX-202 GENE THERAPY IN MALES WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)
- A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND EFFICACY OF A SINGLE INTRAVENOUS DOSE OF SGT-003 IN AMBULANT MALES WITH DUCHENNE MUSCULAR DYSTROPHY
View on source registry